Cardiac anticoagulation therapy plays a pivotal role in the nuanced landscape of cardiovascular care. Tailored to individuals at risk of blood clot formation, this specialized therapy is a key element in preventing potential complications such as strokes or heart attacks. Commonly prescribed for conditions like atrial fibrillation, deep vein thrombosis, or those with mechanical heart valves, cardiac anticoagulation therapy involves the use of medications like warfarin or direct oral anticoagulants. These medications exert their effect by disrupting the blood clotting process, promoting a smoother flow of blood through the heart and vessels. The meticulous administration of cardiac anticoagulation therapy demands vigilant monitoring and personalized dosing to strike an optimal balance between preventing clots and minimizing the risk of bleeding complications. As research in the medical field progresses, ongoing refinements in cardiac anticoagulation therapies hold the promise of enhanced efficacy, reduced side effects, and improved overall outcomes for individuals managing cardiovascular conditions.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States